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Abstract
Background: Human L-tryptase is a mast cell specific trypsin-
like serine protease that is thought to play a key role in the
pathogenesis of diverse allergic and inflammatory disorders like
asthma and psoriasis. The recently resolved crystal structure
revealed that the enzymatically active tetramer consists of four
quasi-identical monomers. The spatial display of the four identical
active sites represents an ideal basis for the rational design of
bivalent inhibitors.
Results : Based on modeling experiments homobivalent inhibi-
tors were constructed using (i) 6A,6D-dideoxy-6A,6D-diamino-L-
cyclodextrin as a rigid template to bridge the space between the
two pairs of identical active sites and (ii) 3-(aminomethyl)benzene
as a headgroup to occupy the arginine/lysine specific S1 subsites. A
comparative analysis of the inhibitory potencies of synthetic
constructs that differ in size and type of the spacer between
headgroup and template revealed that the construct contained two
3-(aminomethyl)benzenesulfonyl-glycine groups linked to the
6A,6D-diamino groups of L-cyclodextrin as an almost ideal
bivalent inhibitor with a cooperativity factor of 1.9 vs. the ideal
value of 2. The bivalent binding mode is supported by the
inhibitor/tetramer ratio of 2:1 required for inactivation of tryptase
and by X-ray analysis of the inhibitor/tryptase complex.
Conclusion : The results obtained with the rigid cyclodextrin
template underlined the importance of a minimal loss of
conformational entropy in bivalent binding, but also showed the
limitations imposed by such rigid core molecules in terms of
optimal occupancy of binding sites and thus of enthalpic strains in
bidentate binding modes. The main advantage of bivalent
inhibitors is their high selectivity for the target enzyme that can
be achieved utilizing the principle of multivalency. ß 2001 Else-
vier Science Ltd. All rights reserved.
Keywords: L-Tryptase; Bivalent inhibitor ; L-Cyclodextrin; Circular
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1. Introduction
Cooperativity plays a central role in folding pathways of
biomolecules into higher order structures as well as in
molecular recognition that leads to biological functions.
It is typically employed when numerous weak interactions
operate simultaneously leading to polyvalent intermolecu-
lar interactions, which are responsible for the selectivity
and avidity of protein/protein or protein/carbohydrate rec-
ognition and thus drive the unidirectional reactions in bio-
chemical cascades [1]. By mimicking nature, this principle
of polyvalency has been largely exploited to modulate car-
bohydrate/protein interactions [2,3] and particularly in the
design of inhibitors of adhesion processes, e.g. of patho-
gens to cell membranes [4^7]. It has also been applied in
the control of cellular signal transduction [8^10] and in the
development of enzyme inhibitors [11^15].
The physical laws that govern such polyvalent binding
of biomolecules have been the object of extensive studies
[1,16^18]. Usually, the contributions of the single binding
subsites to the overall free energy of binding are rational-
ized in terms of their intrinsic binding energies and of a
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connection Gibbs energy that represents the change in the
probability of binding that results from the assembly of
the binding subsites into one molecule [18]. Quanti¢cation
of these contributions is particularly di⁄cult in hetero-
polyvalency. Therefore, homo-polyvalent ligands interact-
ing with identical binding subsites of the receptor molecule
in well de¢ned systems are required to gain a better insight
into the thermodynamics of such molecular recognition
processes. Recently, a well de¢ned system consisting of a
homotrimeric vancomycin construct that binds to a homo-
trimeric ligand was utilized to con¢rm the approximate
additivity of the free binding energies [19,20].
In terms of multivalent enzyme inhibition, until recently
only the thrombin/hirudin complex was known whose X-
ray structure clearly revealed two distinct domain interac-
tions at the active site and the ¢brinogen binding site,
respectively [21]. By exploiting this information, highly
potent hirudin mimetics, e.g. the hirulogs [13], were devel-
oped. These hetero-bivalent inhibitors bind to the two
di¡erent subsites simultaneously, thus leading to a strong
potentiation of a⁄nity and selectivity. With the discovery
of multicatalytic protease complexes and particularly with
the X-ray structure analyses of the eukaryotic proteasome
and human L-tryptase [22^24], two interesting new target
molecules have become available with (pairwise) identical
multiple active sites displayed spatially in a de¢ned geo-
metrical order. This type of architecture of the receptor
molecule is ideally suited for the design of synthetic inhib-
itors based on the principle of oligovalency and for inves-
tigating potential limitations for the additivity of the free
binding energies caused by the chemical structure of the
bivalent ligands.
The 20S proteasome from Saccharomyces cerevisiae ex-
hibits a cylindrical architecture in which the 28 subunits
are assembled as an (K1^K7, L1^L7)2 complex consisting
of four stacked heptameric rings with a spatial arrange-
ment of two sets of three di¡erent active sites in a geo-
metrical array [22]. Due to the bottleneck of the protea-
some entrance that recruits from outside only fully
unfolded linear proteins for digestion and thus signi¢-
cantly restricts the choice of spacers, in a previous study
we used polyoxyethylene (PEG) of appropriate size to
crosslink pairwise the tripeptide aldehydes H-Leu-Leu-
Nle-H and H-Arg-Val-Arg-H as headgroups for the chy-
motryptic L5/L5P and tryptic L2/L2P active site pairs, re-
spectively [25,26]. Although highly selective inhibition of
the chymotrypsin- and trypsin-like activities of the protea-
some was achieved with such constructs, the potency was
increased by only two orders of magnitude compared to
the monovalent inhibitors. This relatively small gain in
free binding energy by the bivalent inhibitors has to be
attributed to the high degree of £exibility of the spacer
and thus to the loss of conformational entropy associated
with the bidentate interaction that makes binding at the
second site energetically less favored.
Di¡erently from the proteasome, the human L-tryptase
tetramer consists of four identical subunits which accord-
ing to X-ray analysis are assembled in a structurally quasi-
equivalent form into a £at ring, with the four active sites
pointing towards an oval central pore [23,24]. This array
of active sites, schematically outlined in Fig. 1, restricts the
access of macromolecular substrates to the digestion
chamber and prevents inhibition of the enzyme by all
known endogenous proteinase inhibitors [27]. However,
the relatively large size of the open central pore should
allow free access of even complex synthetic constructs to
the active sites and thus the use of both £exible and rigid
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Fig. 1. (A) Ribbon representation of the L-tryptase tetramer. The sub-
units A, B, C, and D are colored blue, red, green, and yellow, respec-
tively; Asp-189 at the bottom of each S1 pocket is shown as magenta
CPK representation. (B) Schematic representation of the tryptase tet-
ramer with inter-S1 subsite distances. Asp-189 at the bottom of each S1
pocket is shown as a red asterisk.
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spacers for the rational design of homobivalent and ulti-
mately even of homotetravalent inhibitors.
In view of this unique tetrameric architecture of the
tryptase, in the present study we have investigated the
e¡ects of £exible and rigid templates on the a⁄nity of
bivalent inhibitors. As expected, rigid spacers proved to
be highly superior to £exible ones, but the study also con-
¢rmed that optimal ¢tting of the binding headgroups is
required when utilizing such templates in order to avoid
enthalpic binding strain which can o¡set the gain in en-
tropy, and thus energetically disfavor bivalent binding.
2. Results
2.1. Design of bivalent L-tryptase inhibitors
The trypsin-like speci¢city of L-tryptase is due to the
Asp-189 residue positioned at the bottom of the S1 subsite
which accommodates and binds preferentially arginine/ly-
sine residues or related mimetics as con¢rmed by the X-
ray structure of the L-tryptase/4-amidinophenyl pyruvate
complex [23,24]. The spatial arrangement of the four S1
subsites is shown in Fig. 1. The shortest distance between
the side chain carboxylates of the Asp-189 residues of two
neighboring S1 subsites is that between the subunits A/D
and B/C and corresponds to approximately 33 Aî , whereas
the distance between the S1 subsites of the subunits A/C
and B/D as well as of A/B and D/C is approximately 45 Aî .
To avoid hydrophobic collapses of the spacer/template on
the protein surface of the inner cavity and taking into
account the bulk water that occupies the central pore of
the tryptase tetramer, hydrophilic spacers of due size ap-
peared to be the most suitable candidates for the design of
bivalent ligands. Correspondingly, in the present study
PEG and carbohydrate molecules were used to construct
double-headed inhibitors capable of spanning the distance
between two of the four active sites of the tetramer.
2.2. Homobivalent inhibitors with PEG as spacer
The trypsin-like active sites of the L-tryptase tetramer
are e⁄ciently inhibited by peptidyl arginals as con¢rmed
by the Ki value of the tripeptide aldehyde Ac-Arg-Val-
Arg-H (1) (Table 1) previously synthesized as a monova-
lent inhibitor of the trypsin-like active sites of the protea-
some [25,26]. For a bivalent inhibition of the proteasome,
the amino-free compound 1 was crosslinked with a
(PEG)19ÿ25 polymer to span a distance of 50 Aî and
more. Although largely oversized for the shorter inter-S1
subsite distance of 33 Aî and to a lesser extent for the
larger inter-S1 subsite distance of 45 Aî of the tetramer,
the £exible and highly hydrated bivalent construct 3 was
analyzed for its inhibitory potency. A relatively low in-
crease in potency by only a factor of approximately 10
was obtained with compound 3 as compared to the mono-
valent inhibitor 1. A potential interference by the large
PEG chain can be excluded, as the inhibitory activity of
the pegylated peptide aldehyde 2 is reduced only by a
factor of 2.
2.3. Homobivalent inhibitors with L-cyclodextrin as spacer
As an alternative to the PEG spacer, carbohydrate-
based core structures were analyzed in modeling experi-
ments as appropriate water-solvated templates. The latter
property was expected to reduce the solvation e¡ect on the
binding energies at least concerning the linker moiety to a
minimum. Among the various carbohydrates inspected,
L-cyclodextrin emerged as an ideally sized spacer (Fig.
2). L-Cyclodextrin consists of seven K-D-glucose units
(A^G) which are linked in an K-glycosidic (1C4) manner.
The primary hydroxy groups of the sugar units A and D
Table 1
Inhibition of the L-tryptase tetramer by PEG-linked mono- and bivalent
inhibitors
Compound Structure Ki (nM)
1 Ac-Arg-Val-Arg-H 15
2 HOOC-PEG-CO-Arg-Val-Arg-H 36
3 H-Arg-Val-Arg-OC-PEG-CO-Arg-Val-Arg-H 1.6
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Fig. 2. (A) Ribbon representation of the L-tryptase tetramer with L-cy-
clodextrin positioned in the central pore between the tryptase subunits
A and D. Asp-189 at the bottom of each S1 pocket is shown as magen-
ta CPK representation, L-cyclodextrin in stick representation, and the
sugar units A and D are colored red. (B) Structure of L-cyclodextrin;
the sugar units A and D are colored red.
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are pointing towards the S1 subsites of the adjacent A/D
and B/C subunits in a manner particularly suitable for a
bivalent presentation of binding headgroups. As the space
bridged by the L-cyclodextrin is 13 Aî , this rigid core mol-
ecule was expected to greatly reduce the loss of conforma-
tional entropy of a bivalent ligand upon binding of the
headgroups. Moreover, based on modeling experiments
an easy access of this cyclic carbohydrate into the central
cavity of the tetrameric protease complex was expected.
From a previous use of L-cyclodextrin as carrier of peptide
hormones and inhibitors we also knew that, if su⁄ciently
spaced from the ligand, the cyclic heptaamylose does not
interfere with their recognition and binding to receptor
molecules [28^30].
Docking experiments of various arginine mimetics to
the S1 subsites of L-tryptase as well as our own experi-
mental results with synthetic inhibitors (unpublished re-
sults) indicated a preferred binding of m- over p-substi-
tuted benzenesulfonyl derivatives and an optimal ¢t of
headgroups of the type 3-(aminomethyl)benzenesulfonyl
when grafted onto the two distal positions A and D of
L-cyclodextrin via relatively short spacers.
2.4. Synthesis of L-cyclodextrin-based inhibitors
To functionalize appropriately L-cyclodextrin at the pri-
mary hydroxy functions within units A and D, this cyclic
carbohydrate molecule was converted to 6A,6D-diamino-
6A,6D-dideoxy-L-cyclodextrin (6) adopting the procedure
of Tabushi et al. [31] (Scheme 1). The diamine 6 then
served for the production of various bivalent compounds
containing two 3-(aminomethyl)benzenesulfonyl moieties
grafted onto the template with or without spacers
(Schemes 2 and 3).
To analyze the potential e¡ects of the template on the
binding of headgroups to the S1 pocket of L-tryptase, L-
cyclodextrin was monofunctionalized as the per-acetyl-6-
amino-6-deoxy-L-cyclodextrin derivative 21 essentially as
described previously [28], and was then used for the
synthesis of the monovalent inhibitor 24 as shown in
Scheme 4.
Finally, to assess the e¡ect of the pyramidal sulfona-
mide group on the inhibitory potency of the bivalent con-
structs, it was replaced by the planar carboxamide group
i ii,ii
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OO
O
O
O
O
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4
R ROH OH
6A 6D
Scheme 1. Synthesis of 6A,6D-diamino-6A,6D-dideoxy-L-cyclodextrin
(6). Reaction conditions: (i) biphenyl-4,4P-disulfonyl chloride, pyridine;
(ii) NaN3, N,N-dimethylformamide (DMF); (iii) triphenylphosphine
(PPh3), then 25% aqueous ammonia, DMF.
Scheme 2. Synthesis of 6A,6D-bis[3-(aminomethyl)benzenesulfonylamino]-6A,6D-dideoxy-L-cyclodextrin (8). Reaction conditions: (i) 3-cyanobenzenesul-
fonyl chloride/NaOH, H2O/acetonitrile ; (ii) H2/10% Pd-C, 90% aqueous AcOH.
Scheme 3. Synthesis of 6A,6D-bis[3-(aminomethyl)benzenesulfonyl-glycyl-amino]-6A,6D-dideoxy-L-cyclodextrin (19) and 6A,6D-bis[3-(aminomethyl)benze-
nesulfonyl-L-alanyl-amino]-6A,6D-dideoxy-L-cyclodextrin (20) ; n = 1: glycine; n = 2: L-alanine. Reaction conditions: (i) 3-cyanobenzenesulfonyl chloride/
NaHCO3, H2O/CHCl3 ; (ii) H2/10% Pd-C, AcOH; (iii) di-tert-butyl dicarbonate ((Boc)2O)/NaHCO3, dioxane/H2O (1:1); (iv) 1 N NaOH, tetrahydrofur-
an (THF); (v) 6/benzotriazol-1-yloxy-tris(pyrrolidino)-phosphonium hexa£uorophosphate (PyBOP)/N,N-diisopropylethylamine (DIEA), DMF; (vi) 90%
aqueous tri£uoroacetic acid (TFA).
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using 3-(tert-butoxycarbonylaminomethyl)benzoyl-glycine
(28) to bis-acylate via the PyBOP procedure [32] 6A,6D-
diamino-6A,6D-dideoxy-L-cyclodextrin (6) and to produce
upon acidolytic deprotection the bis-basic compound 30
(Scheme 5).
2.5. Inhibition of L-tryptase by L-cyclodextrin-based
inhibitors
The critical e¡ect of the spacer between the headgroup
3-(aminomethyl)benzenesulfonyl and the L-cyclodextrin
template is re£ected in the inhibition constants of the var-
ious bivalent constructs listed in Table 2. Without spacer
the Ki value of the bivalent inhibitor 8 was found to be
almost identical to that of the headgroup 3-(aminometh-
yl)benzenesulfonyl-glycine methyl ester (11) (Ki 30 and
17 WM, respectively). This clearly shows that this inhibitor
8 is not able to interact with two neighboring S1 subsites
simultaneously and therefore behaves like a monovalent
inhibitor. Conversely, with glycine as spacer, i.e. with
compound 19, a more than 104-fold increase in inhibitory
potency was obtained when compared to the headgroup
11, thus strongly supporting a bidentate binding to the
tetrameric protease. An increase of the spacer length by
a methylene moiety in compound 20, as produced by re-
placing the glycine with a L-alanine residue, is su⁄cient to
reduce the inhibition potency to some extent. Thus, with
glycine as spacer apparently the optimal spacer size was
achieved, unless the additional rotor introduced with the
methylene group leads to an entropic penalty in terms of
loss of conformational entropy.
The high degree of selectivity of L-tryptase inhibition by
the bivalent inhibitor 19 versus trypsin and thrombin is
re£ected by the Ki values reported in Table 3. As expected
from a simple occupation of the S1 subsite, the headgroup
11 is a poor inhibitor of all three enzymes, and both its
Scheme 4. Synthesis of 6-[3-(aminomethyl)benzenesulfonyl-glycylamino]-6-deoxy-L-cyclodextrin (24). Reaction conditions: (i) 15/N-ethyl-NP-(3-dimethyl-
aminopropyl)-carbodiimide hydrochloride (EDC)/1-hydroxybenzotriazole (HOBt), CHCl3 ; (ii) 1 N NaOH, MeOH/H2O; (iii) 90% aqueous TFA.
Scheme 5. Synthesis of 6A,6D-bis[3-(aminomethyl)benzoyl-glycyl-amino]-6A,6D-dideoxy-L-cyclodextrin (30). Reaction conditions: (i) 3-cyanobenzoyl
chloride/NaHCO3, H2O/CHCl3 ; (ii) H2/10% Pd-C, AcOH; (iii) (Boc)2O/NaHCO3, dioxane/H2O (1:1); (iv) 1 N NaOH, THF; (v) 6/PyBOP/DIEA,
DMF; (vi) 90% aqueous TFA.
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mono- and bis-presentation by the cyclodextrin template
does not signi¢cantly alter the a⁄nity for trypsin and
thrombin. Thus exploiting the low a⁄nity of the head-
group for trypsin-like enzymes, with the bivalent inhibitor
19 a more than 104-fold selectivity for L-tryptase was
achieved. As already expected from the inhibitory activity
of construct 8, the L-cyclodextrin moiety itself only slightly
a¡ects the a⁄nity of the headgroup for tryptase as well as
Table 2
Inhibition of the L-tryptase tetramer by L-cyclodextrin-based bivalent inhibitors: in£uence of the spacer length on the inhibitory potency
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for the other enzymes analyzed as evidenced by comparing
the Ki values of the headgroup 11 with that of compound
24 (Table 3). This observation fully agrees with our pre-
vious experiences with L-cyclodextrin as carrier of diverse
other ligands [28^30].
The replacement of the freely rotatable sulfonamide
bond in compound 19 with the planar carboxamide
bond in construct 30 most surprisingly produced a dra-
matic reduction of a⁄nity for tryptase. In fact, comparing
its binding a⁄nity to that of the headgroup 3-(amino-
methyl)benzoyl as glycine methyl ester (26) (Ki 0.4 and
74 WM, respectively), only a 160-fold increased inhibitory
potency was determined for the bivalent construct
(Table 4). This suggests that the limitation of the free
rotation of the headgroup prevents optimal occupation
of the two S1 subsites, most probably due to a penalty
caused by enthalpic strains.
2.6. Bivalent binding of the L-cyclodextrin inhibitor 19 to
L-tryptase
The strong in£uence of the type and size of the spacer
between the carbohydrate template and the headgroups on
binding a⁄nities and the absence of contributions to bind-
ing by the cyclodextrin moiety per se fully support a bi-
valent binding mode of the inhibitor 19 to two adjacent
active sites of the L-tryptase tetramer. Correspondingly,
the expected stoichiometry for inactivation of the A/D
and B/C pairs of active sites is 2:1 for inhibitor 19/tetra-
meric enzyme. Titration of L-tryptase with compound 19
yields a ratio of 1.93 þ 0.1, which fully agrees with the
theoretical one (Fig. 3). Further evidence for the bivalent
binding mode could be derived from X-ray structure anal-
ysis of L-tryptase/inhibitor 19 crystals. Despite the low
resolution (3.2 Aî ), the 2Fobs3Fcalc density map clearly
Table 3
Inhibition of L-tryptase, trypsin, and thrombin by L-cyclodextrin-based mono- and bivalent inhibitors : in£uence of the cyclodextrin moiety on the inhib-
itory potency
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reveals well de¢ned positions of two cyclodextrin moieties
between the A/D and B/C active sites, respectively, in cor-
rect distance for occupancy of the S1 subsites by the iden-
tical headgroups (Fig. 4). The depicted model of the in-
hibitor 19 serves only to illustrate that the position of the
cyclodextrin moiety allows binding of the headgroups into
the speci¢city pockets. At the present state of re¢nement,
the electron density does not allow us to localize the atom
positions of the two identical side chains exactly. The de-
tailed structural analysis will be reported elsewhere.
2.7. Structural stabilization of the tetrameric L-tryptase
with inhibitors
As shown by the X-ray structure, large contact areas
between the subunits A/D and B/C (1075 Aî 2 each) togeth-
er with stabilizing hydrophobic contacts, salt bridges, and
hydrogen bonds involving both main and side chains (Fig.
1) are responsible for the tight assembly of these mono-
mers [23,24]. The contact areas between the subunits A/B
and C/D are signi¢cantly smaller (540 Aî 2), and these in-
terfaces are exclusively hydrophobic in nature. Most
likely, the known tetramer stabilizing e¡ect of high salt
concentrations [33,34] is due to the strengthening of these
hydrophobic interactions and weakening of the arginine/
arginine repulsion within these interfaces. In vivo, L-tryp-
tase is secreted by mast cells as a tetramer stabilized by
heparin proteoglycans [35,36], which are thought to bind
to clusters of positively charged residues on both sides of
the A/B and C/D interface. In the absence of stabilizing
Table 4
Inhibition of the L-tryptase tetramer by L-cyclodextrin-based bivalent inhibitors: in£uence of the replacement of the sulfonyl group by a carbonyl group
on the inhibitory potency
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glycosaminoglycans or high salt concentrations, the enzy-
matically active tetramer rapidly dissociates into the
monomers which are virtually inactive [33,34,37,38]. In
the enzymatically active tetramer, the N-terminal Ile-16
residue of each monomer is inserted into the Ile-16 pocket
and forms a solvent-inaccessible salt bridge between its
K-amino group and the side chain carboxylate of Asp-
194. This salt bridge is found in virtually all mature tryp-
sin-like proteases and is required for the formation of the
functional substrate recognition subsites [39,40]. This re-
arrangement of the active site leads to local alterations of
the environment of a tryptophan residue and thus to a
signi¢cantly altered dichroic contribution in the far-UV
circular dichroism (CD) spectrum that produces a negative
maximum centered at 230 nm. For chymotrypsin this role
was assigned to Trp-141 [41], but Trp-215 has also been
proposed as the responsible residue [42]. The CD spectra
of tryptases from various organisms are also characterized
by this negative dichroic peak at 230 nm, which according
to the amino acid sequence alignment [43,23] could origi-
nate from Trp-130 (tryptase numbering). Upon inactiva-
tion of tryptase, this characteristic dichroic minimum dis-
appears [44,45], thus making it possible to monitor by CD
a conversion of tetrameric tryptase into monomers.
Heat denaturation of L-tryptase in the absence of the
stabilizing heparin and at physiological salt concentration
(150 mM) exhibits a two-phase transition (Fig. 5). In
agreement with similar studies reported previously [44],
the ¢rst transition is characterized by a decrease of the
dichroic intensity at 230 nm and corresponds to the dis-
sociation of the tetramer into monomers and thus parallels
the loss of enzymatic activity. It is followed by a second
transition (Tm = 62.4‡C), which results from thermal dena-
turation of the monomers as assessed by monitoring ther-
mal unfolding of the monomer at 215 nm (data not
shown). Addition of the monovalent inhibitor 11 at con-
centrations su⁄cient to occupy all four active sites led to a
remarkable stabilization of the tetramer (Tm = 48.3‡C). A
stabilizing e¡ect of the peptide aldehyde leupeptin on tryp-
tase against time-dependent spontaneous inactivation has
been reported previously [45]. Cross-bridging of the A/D
and B/C monomers by the bivalent inhibitor 19 results in a
weak, but well detectable increase of the Tm value to
49.9‡C.
3. Discussion
From theoretical considerations on polyvalent binding
Fig. 4. X-ray structure of the L-tryptase tetramer in complex with the bivalent inhibitor 19. The tryptase subunits A (green) and D (yellow) are shown
in ribbon representation with the amino acid residues of the catalytic triad (Ser-195, His-57, and Asp-102) as stick and ball models. The inhibitor 19 is
shown in stick and ball representation, sticks are colored red, C atoms black, O atoms red, N atoms blue, and S atoms yellow.
Fig. 3. Titration of L-tryptase (12.5 nM tetramer, i.e. 50 nM active sites)
with the bivalent inhibitor 19.
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of ligands to receptor molecules, thermodynamic correla-
tions were derived which were validated experimentally by
Whitesides and coworkers [19,20] with the classical study
of the vancomycin system. The thermodynamics of mono-
valent and bivalent inhibition of the L-tryptase tetramer
are outlined in Fig. 6. Ideally, the enthalpy of binding of a
bivalent inhibitor into two identical active sites should
correspond to two times that of the monomer, while the
loss of entropy, in such a case dominated by translational
entropy, should be approximately that of the monomer.
Such ideal bivalent inhibitors require a rigid template that
allows the headgroups to interact with the enzyme binding
subsites without enthalpic strains and with a minimal loss
of conformational entropy. Conversely, for £exible ligands
a high penalty from the conformational entropy can
largely o¡set the favorable translational and rotational
entropy term.
In view of these thermodynamic aspects, the low gain in
binding a⁄nity obtained with the bivalent PEG-based in-
hibitor 3 has to be attributed mainly to its high degree of
£exibility. Although the £exible PEG spacer allows for
binding of the headgroups to the active sites without en-
thalpic strains, the large penalty resulting from the loss of
conformational entropy makes binding at the second site
energetically less favored. Similar low gains in binding
energies have previously been reported for the use of
PEG as spacer of bidentate ligands [6,9]. In the case of
the proteasome where di¡usion into and out of the cata-
lytic chamber is hampered by the bottleneck of the cylin-
drical structure, bivalent binding of such PEG-based in-
hibitors is apparently more favored by their seclusion in
the digestion chamber [25], whereas in the case of the
tryptase tetramer di¡usion into the bulk solvent from
the central pore is not hindered at all.
In the L-cyclodextrin construct 19 only the four bonds
related to the glycine spacer allow for free rotational mo-
tions and thus for optimal occupancy of the S1 binding
pockets. Upon binding, these bonds are probably frozen
into a de¢ned conformation, but the related loss of con-
formational entropy is insu⁄cient to compensate for the
gains in the translational and rotational entropy term.
Correspondingly, the free energies of binding of the biva-
lent inhibitor become additive with the Ki;biW(Ki;mono)2
and a cooperativity factor [1] K= (log Ki;bi)/(log Ki;mono)
of 1.9 versus the theoretical value of 2. This result fully
20 30 40 50 60 70 80 90
-0,2
0,0
0,2
0,4
0,6
0,8
1,0
1,2
Fr
a
ct
io
n
o
fC
D
ch
an
ge
a
t2
30
n
m
Temperature[°C]
Fig. 5. Thermal denaturation of the L-tryptase tetramer and monomer
without stabilizing heparin at low salt conditions (150 mM NaCl). Blue:
L-tryptase tetramer without inhibitor; black: L-tryptase monomer;
green: L-tryptase tetramer in the presence of 1 mM 11 ; red: L-tryptase
tetramer in the presence of 10 WM 19.
D G° m = D H°m -T D S°m
D G° b » 2(D H°m -T D S°m )+ T D S°trans+rot,m
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C
Fig. 6. Thermodynamics of the inhibition of L-tryptase by mono- and
bivalent inhibitors. (A) Binding head. (B) Bivalent inhibitor with per-
fectly ¢tting, rigid spacer. (C) Bivalent inhibitor with £exible spacer.
vG‡m, vH‡m and TvS‡m are the free energy, enthalpy, and entropy of
monovalent inhibition, respectively ; TvS‡transrot;m is the translational
and rotational entropy of monovalent inhibition; vG‡b is the free en-
ergy of bivalent inhibition, and TvS‡conf is the loss of conformational
entropy in the two intramolecular binding events.
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con¢rms the advantage of rigid sca¡olds for the design of
homobivalent inhibitors. However, it also reveals the lim-
its that are derived from the need of optimal ¢tting of
both heads, as small deviations lead to signi¢cant losses
of binding a⁄nity. In fact, a slight increase in the size of
the spacer, i.e. the replacement of the glycine residue with
L-alanine, already a¡ects the inhibitory potency. More
dramatic was the e¡ect of replacing the sulfonamide
bond with a carboxamide bond as the bivalent e¡ect was
almost fully lost. The resulting potentiation of binding
a⁄nity of the dibasic compound 30 (Ki = 0.4 WM versus
Ki = 74 WM of the headgroup 26) does not necessarily re-
sult from a homobivalent binding as it could well derive
from exosite binding of the second basic group. This is
supported by results of X-ray analysis of supposedly ho-
mobivalent dibasic tryptase inhibitors, which were found
to interact with the second basic group at exosites (unpub-
lished results).
4. Signi¢cance
The main advantage of the design of bivalent inhibitors
of multicatalytic protease complexes such as the tetrameric
L-tryptase is certainly the high degree of selectivity that
can be obtained. In fact, the potentiation of binding a⁄n-
ity of weakly binding headgroups with poor a⁄nity for
other monomeric enzymes can be exploited by this ap-
proach to produce highly speci¢c inhibitors. Because there
are strong indications from an increasing number of stud-
ies that tryptase is directly involved in the pathogenesis of
asthma [46^51], the tetrameric architecture of this trypsin-
like serine protease has already been successfully exploited
for the design of dibasic inhibitors. Without knowledge of
the exact structure of the tetramer, some of the dibasic
compounds were too small for bivalent inhibition
[52,53], whereas screening with more or less £exible
spacers of increasing length led to highly potent inhibitors
[49,54^57]. However, potentiation of binding a⁄nities of
dibasic compounds does not necessarily result only from a
more or less optimal homobivalent binding, but could also
derive from less de¢ned exosite interactions.
5. Experimental procedures
5.1. Materials and methods
All reagents and solvents used in the synthesis were of the
highest quality commercially available. L-Cyclodextrin was pur-
chased from Fluka, biphenyl-4,4P-disulfonyl chloride and 3-cya-
nobenzoyl chloride from Aldrich, 3-cyanobenzenesulfonyl chlo-
ride from Maybridge Chemical Company, and the ion exchange
resin Serdolit MB-3 from Serva. Thin layer chromatography
(TLC) was carried out on silica gel 60 plates (Merck AG, Darm-
stadt) and compounds were visualized by chlorine/o-toluidine and
ninhydrin reagents. Cyclodextrin derivatives were detected by
dipping the TLC plates into 5% sulfuric acid in methanol fol-
lowed by heating. Analytical high performance liquid chromatog-
raphy (HPLC) was carried out with Waters equipment (Esch-
born) on Nucleosil 100-5/C8 (Macherey and Nagel, Du«ren)
using a linear gradient of acetonitrile/2% H3PO4 from 5:95 to
80:20 in 12 min, preparative HPLC on Nucleosil 100-5/C18 (Ma-
cherey and Nagel, Du«ren) using a linear gradient of 0.1% aque-
ous TFA/acetonitrile from 98:2 to 68:32 in 30 min. The product
content of the inhibitors with the exception of 8 was determined
by quantitative amino acid analysis of the acid hydrolysates (6 M
HCl; 110‡C; 48 h) performed on a Biotronic amino acid analyzer
(LC 6001). Electrospray ionization mass spectrometry (ESI-MS)
spectra were recorded on PE SCIEX API 165.
5.2. Synthesis
The tripeptide aldehyde Ac-Arg-Val-Arg-H (1) and the related
PEG conjugates 2 and 3 were prepared as described previously
[26].
5.2.1. 6A,6D-Diazido-6A,6D-dideoxy-L-cyclodextrin (5)
To a solution of biphenyl-4,4Pdisulfonyl-A,D-capped L-cyclo-
dextrin (4) [30] (1.40 g, 0.99 mmol) in DMF (20 ml) NaN3
(0.52 g, 7.92 mmol) was added, and the stirred reaction mixture
was kept for 24 h at 70‡C. The solvent was evaporated and the
residue dissolved in water. Upon addition of Serdolit MB-3 until
a pH of approximately 5 was reached, the ion exchange resin was
¢ltered o¡, the water evaporated and the residue reevaporated
from toluene (3U). The white powder was suspended in acetone,
¢ltered o¡, washed successively with acetone, tert-butyl methyl
ether and petroleum ether, and dried at 40‡C in vacuo; yield:
1.10 g (94%); TLC (isopropanol/AcOEt/NH3/H2O, 7:7:5:4) Rf
0.4; ESI-MS: m/z 1185.4 [M+H] ; calcd. for C42H68N6O33 :
1184.4.
5.2.2. 6A,6D-Diamino-6A,6D-dideoxy-L-cyclodextrin (6)
To a stirred solution of 5 (0.475 g, 0.40 mmol) in DMF (10
ml), PPh3 (0.629 g, 2.40 mmol) was added. After 1.5 h, 25%
aqueous ammonia (5 ml) was added and the reaction mixture
was stirred overnight. The solvent was evaporated, the residue
was taken up with water and the insoluble PPh3 oxide was ¢ltered
o¡ and the ¢ltrate evaporated. The product was isolated as white
powder by precipitation from water/acetone; yield: 0.41 g (91%);
TLC (isopropanol/AcOEt/NH3/H2O, 7:7:5:4) Rf 0.25; ESI-MS:
m/z 1133.6 [M+H] ; calcd. for C42H72N2O33 : 1132.4.
5.2.3. 6A,6D-Bis(3-cyanobenzenesulfonyl-amino)-6A,6D-dideoxy-
L-cyclodextrin (7)
To a stirred solution of 6 (100.0 mg, 0.088 mmol) 0.1 N NaOH
(1.76 ml) followed by 3-cyanobenzenesulfonyl chloride (1.76 ml
of a solution (c = 0.1 mol/l) in acetonitrile) was added. After 30
min again 0.1 N NaOH (0.35 ml) and 3-cyanobenzenesulfonyl
chloride (0.35 ml) was added, and stirring was continued for an
additional 2 h. Then the solution was treated with Serdolit MB-3
for 3 h, the ion exchange resin was ¢ltered o¡, and the solvent
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was evaporated. The material obtained was suspended in acetone,
collected by centrifugation, washed successively with acetone,
tert-butyl methyl ether and petroleum ether, and dried at 40‡C
in vacuo; yield: 70 mg (54%); HPLC tR 7.4 min; ESI-MS: m/z
1463.6 [M+H] ; calcd. for C56H78N4O37S2 : 1462.4.
5.2.4. 6A,6D-Bis[3-(aminomethyl)benzenesulfonylamino]-6A,6D-
dideoxy-L-cyclodextrin (8)
7 (60.0 mg, 0.041 mmol) in 90% AcOH (180 ml) was hydro-
genated over 10% Pd-C at atmospheric pressure. After 24 h the
solvent was removed in vacuo and the residual oil was evaporated
from toluene (3U). The crude product was puri¢ed by prepara-
tive HPLC and the homogeneous fractions were collected and
lyophilized. The product was obtained as bistri£uoroacetate;
yield: 26 mg (37%); HPLC tR 6.0 min; ESI-MS: m/z 736.4
[M+2H]2 ; calcd. for C56H86N4O37S2 : 1470.4.
5.2.5. 3-(Aminomethyl)benzenesulfonyl-glycine methyl ester (11)
3-Cyanobenzenesulfonyl-glycine methyl ester (9) (0.80 g, 3.14
mmol; prepared by standard procedures from 3-cyanobenzene-
sulfonyl chloride and glycine methyl ester) was hydrogenated
over 10% Pd-C at atmospheric pressure in AcOH (75 ml). The
reduction was completed within 5 h (TLC control) and the cata-
lyst was ¢ltered o¡. The ¢ltrate was concentrated and the result-
ing oil was evaporated from toluene (3U). The title compound
was isolated in the acetate form as a white powder by precipita-
tion from MeOH/tert-butyl methyl ether; yield: 0.76 g (76%);
TLC (n-butanol/AcOH/H2O/AcOEt, 3:1:1:5) Rf 0.15; product
content: 60.9%; ESI-MS: m/z 259.0 [M+H] ; calcd. for
C10H14N2O4S: 258.0.
5.2.6. 3-(Aminomethyl)benzenesulfonyl-L-alanine methyl ester
(12)
3-Cyanobenzenesulfonyl-L-alanine methyl ester (10) (obtained
by standard procedures from 3-cyanobenzenesulfonyl chloride
and L-alanine methyl ester) was hydrogenated as described for
11. The product was isolated in the acetate form; yield: 74%;
TLC (n-butanol/AcOH/H2O/AcOEt, 3:1:1:5) Rf 0.2; ESI-MS:
m/z 273.2 [M+H] ; calcd. for C11H16N2O4S: 272.0.
5.2.7. 3-(tert-Butoxycarbonylaminomethyl)benzenesulfonyl glycine
(15)
To a stirred solution of 11 (0.60 g, 1.88 mmol) in dioxane/H2O
(1:1, 30 ml), NaHCO3 (0.158 g, 1.88 mmol) followed by (Boc)2O
(0.451 g, 2.07 mmol) was added. After 1 h, an additional portion
of (Boc)2O (0.205 g, 0.94 mmol) was added and the solution
stirred for a further 30 min. Then the solvent was evaporated
to dryness; the resulting oil was dissolved in THF (30 ml) and
0.1 N NaOH (19 ml) was added dropwise. After 24 h, the solvent
was evaporated, the residual oil dissolved in water (100 ml) and
washed with AcOEt (3U50 ml). The aqueous phase was acidi¢ed
with 5% aq KHSO4 and extracted with AcOEt (3U50 ml), the
combined organic layers were washed with brine (30 ml) and
dried (Na2SO4). The solvent was evaporated and the product
was isolated by precipitation form AcOEt/petroleum ether as a
colorless powder; yield: 0.45 g (70%); TLC (n-butanol/AcOH/
H2O/AcOEt, 3:1:1:5) Rf 0.8; ESI-MS: m/z 367.2 [M+Na] ;
calcd. for C14H20N2O6S: 344.1.
5.2.8. 3-(tert-Butoxycarbonylaminomethyl)benzenesulfonyl-L-
alanine (16)
The title compound was obtained from 12 as described for 15 ;
yield: 76%; TLC (cyclohexane/CHCl3/AcOH, 45:45:10) Rf 0.1;
ESI-MS: m/z 359.0 [M+H] ; calcd. for C15H22N2O6S: 358.1.
5.2.9. 6A,6D-Bis[3-(tert-butoxycarbonylaminomethyl)benzene-
sulfonyl-glycyl-amino]-6A,6D-dideoxy-L-cyclodextrin (17)
To a stirred solution of 6 (100.0 mg, 0.088 mmol), 15 (72.9 mg,
0.211 mmol), and PyBOP (110.2 mg, 0.211 mmol) in DMF (7.5
ml), DIEA (36.5 Wl, 0.211 mmol) was added. After 24 h, the
solvent was evaporated and the oily residue treated with acetone.
The colorless precipitate was collected by centrifugation, washed
successively with acetone, tert-butylmethyl ether, and petroleum
ether and dried at 40‡C in vacuo; yield: 105.0 mg (67%); HPLC:
tR 6.7 min; ESI-MS: m/z 1786.8 [M+H] ; calcd. for
C70H108N6O43S2 : 1784.6.
5.2.10. 6A,6D-Bis[3-(tert-butoxycarbonylaminomethyl)benzene-
sulfonyl-L-alanyl-amino]-6A,6D-dideoxy-L-
cyclodextrin (18)
The title compound was obtained from 6 and 16 as described
for 17 ; yield: 71%; HPLC: tR 8.3 min; ESI-MS: m/z 1815.2
[M+H] ; calcd. for C72H112N6O43S2 : 1812.6.
5.2.11. 6A,6D-Bis[3-(aminomethyl)benzenesulfonyl-glycyl-
amino]-6A,6D-dideoxy-L-cyclodextrin (19)
17 (100.0 mg, 0.055 mmol) was dissolved in ice-cold 90% TFA
(10 ml). After 3 h, the acid was removed in vacuo and the resid-
ual oil was evaporated from toluene (3U). The title compound
was isolated as bistri£uoroacetate by precipitation from water/
acetone; yield: 85.0 mg (85%); HPLC tR 4.0 min; product con-
tent: 32.0%; ESI-MS: m/z 793.4 [M+2H]2 ; calcd. for
C60H92N6O39S2 : 1584.5.
5.2.12. 6A,6D-Bis[3-(aminomethyl)benzenesulfonyl-L-alanyl-
amino]-6A,6D-dideoxy-L-cyclodextrin (20)
The title compound was obtained from 18 as bistri£uoroacetate
as described for 19 ; yield: 52%; HPLC tR 2.6 min; product
content: 31.1%; ESI-MS: m/z 807.4 [M+2H]2 ; calcd. for
C62H96N6O39S2 : 1612.5.
5.2.13. Mono-{2,3-di-O-acetyl-6-[3-(tert-butoxycarbonylaminom-
ethyl)benzenesulfonyl-glycyl-amino]-6-deoxy}-hexakis-
(2,3,6-tri-O-acetyl)-L-cyclodextrin (22)
To a stirred solution of mono-(2,3-di-O-acetyl-6-amino-6-de-
oxy)-hexakis-(2,3,6-tri-O-acetyl)-L-cyclodextrin (21) [27] (100.0
mg, 0.050 mmol), 15 (20.9 mg, 0.060 mmol), and HOBt (8.2
mg, 0.060 mmol) in CHCl3 (5 ml), EDC (11.6 mg, 0.060 mmol)
was added. After 24 h, the solvent was evaporated and the crude
residue was puri¢ed on a silica gel column (3U7 cm) using tol-
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uene/EtOH (2:1) as eluent. Evaporation of the solvent furnished
a white solid; yield: 106.0 mg (92%); TLC (toluene/EtOH, 2:1)
Rf 0.7; ESI-MS: m/z 2318.8 [M+H2O+H] ; calcd. for
C96H129N3O59S: 2299.7.
5.2.14. 6-[3-(tert-Butoxycarbonylaminomethyl)benzenesulfonyl-
glycyl-amino]-6-deoxy-L-cyclodextrin (23)
To a stirred solution of 22 (106 mg, 0.046 mmol) in MeOH (10
ml) 0.1 N NaOH (1.10 ml) was added. The precipitate which had
been formed after a short period was dissolved by adding water.
After 4 h, Serdolit MB-3 was added. After the pH had reached a
value of about 5, the ion exchange resin was ¢ltered o¡ and the
solvent was evaporated. The title compound was isolated by pre-
cipitation from water/acetone; yield: 57 mg (85%); HPLC tR 5.9
min; ESI-MS: m/z 1460.6 [M+H] ; calcd. for C56H89N3O39S:
1459.5.
5.2.15. 6-[3-(Aminomethyl)benzenesulfonyl-glycylamino]-
6-deoxy-L-cyclodextrin (24)
The acidolytic cleavage of the tert-butoxycarbonyl (Boc) group
from 23 was performed as described for 19. The product was
isolated as tri£uoroacetate; yield: 59 mg (quant.); HPLC tR 4.3
min; product content: 45.3%; ESI-MS: m/z 1360.6 [M+H] ;
calcd. for C51H81N3O37S: 1359.4.
5.2.16. 3-(Aminomethyl)benzoyl-glycine methyl ester (26)
3-Cyanobenzoyl-glycine methyl ester (25) (obtained by stan-
dard procedures from 3-cyanobenzoyl chloride and glycine meth-
yl ester) was hydrogenated as described for 11 and isolated as
hydrochloride; yield: 66%; TLC (CHCl3/MeOH/AcOH, 8:8:1)
Rf 0.4; product content: 90.3%; ESI-MS: m/z 223.0 [M+H] ;
calcd. for C11H14N2O3 : 222.1.
5.2.17. 3-(tert-Butoxycarbonylaminomethyl)benzoyl-glycine (28)
The title compound was obtained from 26 as described for
15 ; yield: 71%; TLC (n-butanol/AcOH/H2O/AcOEt, 3:1:1:5)
Rf 0.8; ESI-MS: m/z 309.2 [M+H] ; calcd. for C15H20N2O5 :
308.1.
5.2.18. 6A,6D-Bis[3-(tert-butoxycarbonylaminomethyl)benzoyl-
glycyl-amino]-6A,6D-dideoxy-L-cyclodextrin (29)
The title compound was obtained from 6 and 28 as described
for 17 ; yield: 72%; HPLC tR 8.0 min; ESI-MS: m/z 1714.0
[M+H] ; calcd. for C72H108N6O41 : 1712.6.
5.2.19. 6A,6D-Bis[3-(aminomethyl)benzoyl-glycyl-amino]-6A,6D-
dideoxy-L-cyclodextrin (30)
The title compound was obtained from 29 as bistri£uoroacetate
as described for 19 ; yield: 94%; HPLC tR 5.6 min; product
content: 81.6%; ESI-MS: m/z 757.4 [M+2H]2 ; calcd. for
C62H92N6O37 : 1512.5.
5.3. Kinetic measurements
Equilibrium dissociation constants (Ki) for the complexes of
the inhibitors with tryptase, thrombin, and trypsin were deter-
mined essentially as described previously [58]. Brie£y, human
L-tryptase isolated from lung tissue or produced recombinantly,
human thrombin, and bovine pancreatic trypsin were standar-
dized by active site titration using 4-methylumbelliferyl p-guani-
dinobenzoate. A constant concentration of an enzyme (0.1^1 nM;
[E]6Ki) was incubated with increasing concentrations of an in-
hibitor for 1 h. Subsequently the residual enzyme activity was
measured by following the hydrolysis of a £uorogenic substrate
in a Biolumin 960 microplate reader (Amersham). Apparent Ki
values were obtained by ¢tting the steady-state velocities to the
equation for tight-binding inhibitors [59] using non-linear regres-
sion analysis, and Ki values calculated by correction for the com-
petition between inhibitor and substrate. Similarly, the stoichiom-
etry of the interaction of inhibitor 19 with the tryptase tetramer
was determined; however, an active site concentration of 50 nM
([E]/KiW80) was used.
5.4. CD measurements
The CD spectra were recorded on a Jasco spectropolarimeter J-
715 equipped with a temperature-controlled cell holder (Model
PFD-350S) using a quartz cell with a path length of 0.1 cm. For
thermal denaturation a heating rate of 30‡C/h was applied. So-
lutions of L-tryptase as tetramer (6.7 WM) and monomer (26.8
WM) were prepared in 50 mM Tris^HCl bu¡er containing 150
mM NaCl (pH 7.6) and concentrations of the bivalent inhibitor
19 (10 WM) and monovalent inhibitor 11 (1 mM) to ascertain
virtually full occupancy of the S1 subsites.
5.5. X-ray analysis
The successful crystallization of previously inhibited and re-
combinant L-tryptase at room temperature using vapor di¡usion
methods will be published elsewhere. Initial small crystals of al-
most cubic shape were grown within a week and used for macro-
seeding. The ¢nal crystals, 100U100U80 Wm in size, su¡ered
from radiation damage such that cryo conditions were required.
Data collection was performed at 100 K at the wiggler beamline
BW6 at DORIS (Deutsches Elektronensynchrotron, Hamburg)
using a CCD detector (Mar Research, Hamburg), a Cryostream
cryosystem (Oxford Cryosystems, Oxford) and £ash-frozen crys-
tals. The data were measured in frames of 0.8‡ through a con-
tinuous angular range of 180‡. The crystal belonged to space
group P1 with unit cell dimensions of a = 107.35 Aî , b = 107.91
Aî , c = 109.04 Aî , K= 89.92‡, L= 89.44‡, Q= 120.36‡. Freezing
caused slight disorder within the crystal lattice, resulting in a
low completeness of 87.3%. The current crystallographic R factor
is 31% (Rfree = 37%).
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